Assenagon Asset Management S.A. Sells 19,700 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Assenagon Asset Management S.A. lessened its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 34.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,917 shares of the company’s stock after selling 19,700 shares during the period. Assenagon Asset Management S.A. owned approximately 0.07% of Design Therapeutics worth $142,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in shares of Design Therapeutics by 4.7% in the 4th quarter. Rhumbline Advisers now owns 52,932 shares of the company’s stock worth $327,000 after purchasing an additional 2,365 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Design Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 761,640 shares of the company’s stock worth $4,700,000 after purchasing an additional 3,090 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Design Therapeutics by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company’s stock worth $114,000 after purchasing an additional 4,013 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Design Therapeutics by 19.9% in the 4th quarter. American Century Companies Inc. now owns 39,115 shares of the company’s stock worth $241,000 after purchasing an additional 6,481 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of Design Therapeutics by 7.2% in the 4th quarter. Barclays PLC now owns 103,571 shares of the company’s stock worth $639,000 after purchasing an additional 6,936 shares in the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Trading Down 1.3%

Design Therapeutics stock opened at $3.74 on Friday. The firm has a market cap of $212.32 million, a price-to-earnings ratio of -3.78 and a beta of 1.62. The stock has a fifty day simple moving average of $3.83 and a two-hundred day simple moving average of $4.54. Design Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $7.77.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). On average, equities research analysts forecast that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.